Atherosclerosis
Volume 183, Issue 1 , Pages 1-16 , November 2005

Rho and vascular disease

Received 29 November 2004 ,Revised 27 April 2005 ,Accepted 29 April 2005.

References 

  1. Hall A. Rho GTPases and the actin cytoskeleton. Science. 1998;279:509–514
  2. Hall A, Paterson HF, Adamson P, Ridley AJ. Cellular responses regulated by Rho-related small GTP-binding proteins. J Biochem. 1993;340:267–271
  3. Olson MF, Ashworth A, Hall A. An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1. Science. 1995;269:1270–1272
  4. Hoshijima M, Sah VP, Wang Y, Chien KR, Brown JH. The low molecular weight GTPase Rho regulates myofibril formation and organization in neonatal rat ventricular myocytes. Involvement of Rho kinase. J Biol Chem. 1998;273:7725–7730
  5. Takano H, Komuro I, Oka T, et al. The Rho family G proteins play a critical role in muscle differentiation. Mol Cell Biol. 1998;18:1580–1589
  6. Senda T, Horiguchi Y, Umemoto M, Sugimoto N, Matsuda M. Bordetella bronchiseptica dermonecrotizing toxin, which activates a small GTP-binding protein Rho, induces membrane organelle proliferation and caveolae formation. Exp Cell Res. 1997;230:163–168
  7. Hirata K, Kikuchi A, Sasaki T, et al. Involvement of Rho p21 in the GTP-enhanced calcium ion sensitivity of smooth muscle contraction. J Biol Chem. 1992;267:8719–8722
  8. Mack CP, Somlyo AV, Hautmann M, Somlyo AP, Owens GK. Smooth muscle differentiation marker gene expression is regulated by RhoA-mediated actin polymerization. J Biol Chem. 2001;276:341–347
  9. Worth NF, Campbell GR, Campbell JH, Rolfe BE. Rho expression and activation in vascular smooth muscle cells. Cell Motil Cytoskeleton. 2004;59:189–200
  10. Worth NF, Campbell GR, Rolfe BE. A role for rho in smooth muscle phenotypic regulation. Ann N Y Acad Sci. 2001;947:316–322.
  11. Aepfelbacher M, Essler M, Huber E, Sugai M, Weber PC. Bacterial toxins block endothelial wound repair. Evidence that Rho GTPases control cytoskeletal rearrangements in migrating endothelial cells. Arterioscler Thromb Vasc Biol. 1997;17:1623–1629
  12. Laufs U, Liao JK. Targeting Rho in cardiovascular disease. Circ Res. 2000;87:526–528
  13. Madaule P, Axel R. A novel Ras-related gene family. Cell. 1985;41:31–40
  14. Takai Y, Sasaki T, Tanaka K, Nakanishi H. Rho as a regulator of the cytoskeleton. Trends Biochem Sci. 1995;20:227–231
  15. Wennerberg K, Der CJ. Rho-family GTPases: it's not only Rac and Rho (and I like it). J Cell Sci. 2004;117:1301–1312
  16. Hall A. The Rho subfamily of small GTPases. In:  Zerial M,  Huber L editor. Guidebook to the small GTPases. Oxford: Oxford University Press; 1995;p. 211
  17. Adamson P, Marshall CJ, Hall A, Tilbrook PA. Post-translational modifications of p21rho proteins. J Biol Chem. 1992;267:20033–20038
  18. Allal C, Favre G, Couderc B, et al. RhoA prenylation is required for promotion of cell growth and transformation and cytoskeleton organization but not for induction of serum response element transcription. J Biol Chem. 2000;275:31001–31008
  19. Ridley AJ, Hall A. The small GTP-binding protein Rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell. 1992;70:389–399
  20. Ridley AJ. Microinjection of Rho and Rac into quiescent Swiss 3T3 cells. Methods Enzymol. 1995;256313–256320
  21. Nobes CD, Hall A. Rho Rac and Cdc42 GTPases: regulators of actin structures, cell adhesion and motility. Biochem Soc Trans. 1995;23:456–459
  22. Ridley AJ. Rho: theme and variations. Curr Biol. 1996;6:1256–1264
  23. Johnson DI. Cdc42: an essential Rho-type GTPase controlling eukaryotic cell polarity. Microbiol Mol Biol Rev. 1999;63:54–105
  24. Nabi IR. The polarization of the motile cell. J Cell Sci. 1999;112:1803–1811
  25. Small JV, Rottner K, Kaverina I. Functional design in the actin cytoskeleton. Curr Opin Cell Biol. 1999;11:54–60
  26. Ghosh PM, Mott GE, Ghosh Choudhury N, et al. Lovastatin induces apoptosis by inhibiting mitotic and post-mitotic events in cultured mesangial cells. Biochim Biophys Acta. 1997;1359:13–24
  27. Esteve P, Embade N, Perona R, et al. Rho-regulated signals induce apoptosis in vitro and in vivo by a p53-independent, but Bcl2 dependent pathway. Oncogene. 1998;17:1855–1869
  28. Gomez J, Martinez C, Giry M, Garcia A, Rebollo A. Rho prevents apoptosis through Bcl-2 expression: implications for interleukin-2 receptor signal transduction. Eur J Immunol. 1997;27:2793–2799
  29. Hill CS, Wynne J, Treisman R. The Rho family GTPases RhoA, Rac1, and Cdc42Hs regulate transcriptional activation by SRF. Cell. 1995;81:1159–1170
  30. Murai K, Treisman R. Interaction of serum response factor (SRF) with the Elk-1 B box inhibits RhoA-actin signaling to SRF and potentiates transcriptional activation by Elk-1. Mol Cell Biol. 2002;22:7083–7092
  31. Kosako H, Goto H, Yanagida M, et al. Specific accumulation of Rho-associated kinase at the cleavage furrow during cytokinesis: cleavage furrow-specific phosphorylation of intermediate filaments. Oncogene. 1999;18:2783–2788
  32. Bishop AL, Hall A. Rho GTPases and their effector proteins. Biochem J. 2000;348(Pt 2):241–255
  33. Kranenburg O, Poland M, Gebbink M, Oomen L, Moolenaar WH. Dissociation of LPA-induced cytoskeletal contraction from stress fiber formation by differential localization of RhoA. J Cell Sci. 1997;110:2417–2427
  34. Seasholtz TM, Majumdar M, Kaplan DD, Brown JH. Rho and Rho kinase mediate thrombin-stimulated vascular smooth muscle cell DNA synthesis and migration. Circ Res. 1999;84:1186–1193
  35. Kishi H, Bao J, Kohama K. Inhibitory effects of ML-9, wortmannin, and Y-27632 on the chemotaxis of vascular smooth muscle cells in response to platelet-derived growth factor-BB. J Biochem (Tokyo). 2000;128:719–722
  36. Funakoshi Y, Ichiki T, Shimokawa H, et al. Rho-kinase mediates angiotensin II-induced monocyte chemoattractant protein-1 expression in rat vascular smooth muscle cells. Hypertension. 2001;38:100–104
  37. Siess W, Zangl KJ, Essler M, et al. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc Natl Acad Sci USA. 1999;96:6931–6936
  38. Xu CB, Hansen-Schwartz J, Edvinsson L. Sphingosine signaling and atherogenesis. Acta Pharmacol Sin. 2004;25:849–854
  39. Yamamoto Y, Ikegaki I, Sasaki Y, Uchida T. The protein kinase inhibitor fasudil protects against ischemic myocardial injury induced by endothelin-1 in the rabbit. J Cardiovasc Pharmacol. 2000;35:203–211
  40. DeMali KA, Wennerberg K, Burridge K. Integrin signaling to the actin cytoskeleton. Curr Opin Cell Biol. 2003;15:572–582
  41. Braga VM. Cell–cell adhesion and signalling. Curr Opin Cell Biol. 2002;14:546–556
  42. Numaguchi K, Eguchi S, Yamakawa T, Motley ED, Inagami T. Mechanotransduction of rat aortic vascular smooth muscle cells requires RhoA and intact actin filaments. Circ Res. 1999;85:5–11
  43. Li S, Chen BP, Azuma N, et al. Distinct roles for the small GTPases Cdc42 and Rho in endothelial responses to shear stress. J Clin Invest. 1999;103:1141–1150
  44. Wojciak-Stothard B, Ridley AJ. Shear stress-induced endothelial cell polarization is mediated by Rho and Rac but not Cdc42 or PI 3-kinases. J Cell Biol. 2003;161:429–439
  45. Ridley AJ. Rho-related proteins: actin cytoskeleton and cell cycle. Curr Opin Gen Cell Dev. 1995;5:24–30
  46. Zigmond SH. Signal transduction and actin filament organization. Curr Opin Cell Biol. 1996;8:66–73
  47. Van Aelst L, D'Souza Schorey C. Rho GTPases and signaling networks. Genes Dev. 1997;11:2295–2322
  48. Chrzanowska-Wodnicka M, Burridge K. Rho-stimulated contractility drives the formation of stress fibers and focal adhesions. J Cell Biol. 1996;133:1403–1415
  49. Kimura K, Ito M, Amano M, et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science. 1996;12:245–248
  50. Amano M, Ito M, Kimura K, et al. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J Biol Chem. 1996;271:20246–20249
  51. Burridge K, Wennerberg K. Rho and Rac take center stage. Cell. 2004;116:167–179
  52. Li F, Higgs HN. The mouse Formin mDia1 is a potent actin nucleation factor regulated by autoinhibition. Curr Biol. 2003;13:1335–1340
  53. Watanabe N, Kato T, Fujita A, Ishizaki T, Narumiya S. Cooperation between mDia1 and ROCK in Rho-induced actin reorganization. Nat Cell Biol. 1999;1:136–143
  54. Kimura K, Fukata Y, Matsuoka Y, et al. Regulation of the association of adducin with actin filaments by Rho-associated kinase (Rho-kinase) and myosin phosphatase. J Biol Chem. 1998;273:5542–5548
  55. Maekawa M, Ishizaki T, Boku S, et al. Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. Science. 1999;285:895–898
  56. Janmey PA, Stossel TP. Modulation of gelsolin function by phosphatidylinositol 4,5-bisphosphate. Nature. 1987;325:362–364
  57. Chong LD, Traynor-Kaplan A, Bokoch GM, Schwartz MA. The small GTP-binding protein Rho regulates a phosphatidylinositol 4-phosphate 5-kinase in mammalian cells. Cell. 1994;79:507–513
  58. Bagrodia S, Taylor SJ, Creasy CL, Chernoff J, Cerione RA. Identification of a mouse p21Cdc42/Rac activated kinase. J Biol Chem. 1995;270:22731–22737
  59. Van Aelst L, Joneson T, Bar-Sagi D. Identification of a novel Rac1-interacting protein involved in membrane ruffling. EMBO J. 1996;15:3778–3786
  60. Miki H, Suetsugu S, Takenawa T. WAVE, a novel WASP-family protein involved in actin reorganization induced by Rac. EMBO J. 1998;17:6932–6941
  61. Symons M. Rho family GTPases: the cytoskeleton and beyond. Trends Biochem Sci. 1996;21:178–181
  62. Nakagawa H, Miki H, Ito M, et al. N-WASP WAVE and Mena play different roles in the organization of actin cytoskeleton in lamellipodia. J Cell Sci. 2001;114:1555–1565
  63. Settleman J, Albright CF, Foster LC, Weinberg RA. Association between GTPase activators for Rho and Ras families. Nature. 1992;359:153–154
  64. Minden A, Lin A, Claret FX, Abo A, Karin M. Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs. Cell. 1995;81:1147–1157
  65. Bagrodia S, Derijard B, Davis RJ, Cerione RA. Cdc42 and PAK-mediated signaling leads to Jun kinase and p38 mitogen-activated protein kinase activation. J Biol Chem. 1995;270:27995–27998
  66. Perona R, Montaner S, Saniger L, et al. Activation of the nuclear factor-kB by Rho, CDC42, and Rac-1 proteins. Genes Dev. 1997;11:463–475
  67. Montaner S, Perona R, Saniger L, Lacal JC. Multiple signalling pathways lead to the activation of the nuclear factor kappaB by the Rho family of GTPases. J Biol Chem. 1998;273:12779–12785
  68. Pelletier S, Duhamel F, Coulombe P, Popoff MR, Meloche S. Rho family GTPases are required for activation of Jak/STAT signaling by G protein-coupled receptors. Mol Cell Biol. 2003;23:1316–1333
  69. Abo A, Pick E, Hall A, et al. Activation of the NADPH oxidase involves the small GTP-binding protein p21rac1. Nature. 1991;353:668–670
  70. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343:425–430
  71. Takai Y, Sasaki T, Matozaki T. Small GTP-binding proteins. Physiol Rev. 2001;81:153–208
  72. Ridley AJ. Rho family proteins and regulation of the actin cytoskeleton. Prog Mol Subcell Biol. 1999;22:1–22
  73. Wojciak Stothard B, Potempa S, Eichholtz T, Ridley AJ. Rho and Rac but not Cdc42 regulate endothelial cell permeability. J Cell Sci. 2001;114:1343–1355
  74. Feig LA. Tools of the trade: use of dominant-inhibitory mutants of Ras-family GTPases. Nat Cell Biol. 1999;1:E25–E27
  75. Alberts AS, Geneste O, Treisman R. Activation of SRF-regulated chromosomal templates by Rho-family GTPases requires a signal that also induces H4 hyperacetylation. Cell. 1998;92:475–487
  76. Osada S, Izawa M, Koyama T, Hirai S, Ohno S. A domain containing the Cdc42/Rac interactive binding (CRIB) region of p65PAK inhibits transcriptional activation and cell transformation mediated by the Ras-Rac pathway. FEBS Lett. 1997;404:227–233
  77. Schmidt G, Aktories K. Bacterial cytotoxins target Rho GTPases. Naturwissenschaften. 1998;85:253–261
  78. Aktories K, Just I. In vitro ADP-ribosylation of Rho by bacterial ADP-ribosyltransferases. Methods Enzymol. 1995;256:184–195
  79. Aktories K. Rho proteins: targets for bacterial toxins. Trends Microbiol. 1997;5:282–288
  80. Sehr P, Joseph G, Genth H, et al. Glucosylation and ADP ribosylation of rho proteins: effects on nucleotide binding, GTPase activity, and effector coupling. Biochemistry. 1998;37:5296–5304
  81. Aktories K, Schmidt G, Just I. Rho GTPases as targets of bacterial protein toxins. Biol Chem. 2000;381:421–426
  82. Fu Y, Galan JE. A salmonella protein antagonizes Rac-1 and Cdc42 to mediate host-cell recovery after bacterial invasion. Nature. 1999;401:293–297
  83. Lerm M, Schmidt G, Aktories K. Bacterial protein toxins targeting rho GTPases. FEMS Microbiol Lett. 2000;188:1–6
  84. Uehata M, Ishizaki T, Satoh H, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 1997;389:990–994
  85. Sahai E, Ishizaki T, Narumiya S, Treisman R. Transformation mediated by RhoA requires activity of ROCK kinases. Curr Biol. 1999;9:136–145
  86. Narumiya S, Ishizaki T, Uehata M. Use and properties of ROCK-specific inhibitor Y-27632. Methods Enzymol. 2000;325:273–284
  87. Amano M, Chihara K, Nakamura N, et al. The COOH terminus of Rho-kinase negatively regulates rho-kinase activity. J Biol Chem. 1999;274:32418–32424
  88. Ikenoya M, Hidaka H, Hosoya T, et al. Inhibition of rho-kinase-induced myristoylated alanine-rich C kinase substrate (MARCKS) phosphorylation in human neuronal cells by H-1152, a novel and specific Rho-kinase inhibitor. J Neurochem. 2002;81:9–16
  89. Ross R. Atherosclerosis: a defense mechanism gone awry. Am J Pathol. 1993;142:987–1002
  90. Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis. 2003;170:191–203
  91. Campbell GR, Campbell JH. Smooth muscle diversity: implications for the question; what is a smooth muscle cell?. Biomed Res. 1997;8:81–125
  92. Manderson JA, Mosse PRL , Safstrom JA, Ypung SM, Campbell GR. Balloon catheter injury to rabbit carotid artery. Part 1: Changes in smooth muscle phenotype. Arteriosclerosis. 1989;9:289–298
  93. Saitoh S, Saito T, Ohwada T, et al. Morphological and functional changes in coronary vessel evoked by repeated endothelial injury in pigs. Cardiovasc Res. 1998;38:772–781
  94. Eto Y, Shimokawa H, Hiroki J, et al. Gene transfer of dominant negative Rho kinase suppresses neointimal formation after balloon injury in pigs. Am J Physiol Heart Circ Physiol. 2000;278:H1744–H1750
  95. Mallat Z, Gojova A, Sauzeau V, et al. Rho-associated protein kinase contributes to early atherosclerotic lesion formation in mice. Circ Res. 2003;93:884–888
  96. Kataoka C, Egashira K, Inoue S, et al. Important role of Rho-kinase in the pathogenesis of cardiovascular inflammation and remodeling induced by long-term blockade of nitric oxide synthesis in rats. Hypertension. 2002;39:245–250
  97. van Hinsbergh WM. Endothelial permeability for macromolecules Mechanistic aspects of pathophysiological modulation. Arterioscler Thromb Vasc Biol. 1997;17:1018–1023
  98. Lum H, Malik AB. Regulation of vascular endothelial barrier function. Am J Physiol. 1994;267:223–241
  99. Aepfelbacher M, Essler M. Disturbance of endothelial barrier function by bacterial toxins and atherogenic mediators: a role for Rho/Rho kinase. Cell Microbiol. 2001;3:649–658
  100. Carmeliet P, Collen D. Molecular basis of angiogenesis. Role of VEGF and VE-cadherin. Ann N Y Acad Sci. 2000;902:249–262[discussion 262–4]
  101. Bhakdi S, Walev I, Jonas D, et al. Pathogenesis of sepsis syndrome: possible relevance of pore-forming bacterial toxins. Curr Top Microbiol Immunol. 1996;216:101–118
  102. Vouret Craviari V, Boquet P, Pouyssegur J, Van Obberghen Schilling E. Regulation of the actin cytoskeleton by thrombin in human endothelial cells: role of Rho proteins in endothelial barrier function. Mol Biol Cell. 1998;9:2639–2653
  103. van Wetering S, van Buul JD, Quik S, et al. Reactive oxygen species mediate Rac-induced loss of cell–cell adhesion in primary human endothelial cells. J Cell Sci. 2002;115:1837–1846
  104. Carbajal JM, Schaeffer RC. RhoA inactivation enhances endothelial barrier function. Am J Physiol. 1999;277:955–964
  105. van Nieuw Amerongen GP, Vermeer MA, van Hinsbergh VW. Role of RhoA and Rho kinase in lysophosphatidic acid-induced endothelial barrier dysfunction. Arterioscler Thromb Vasc Biol. 2000;20:E127–E133
  106. Wojciak-Stothard B, Ridley AJ. Rho GTPases and the regulation of endothelial permeability. Vasc Pharmacol. 2002;39:187–199
  107. Waschke J, Baumgartner W, Adamson RH, et al. Requirement of Rac activity for maintenance of capillary endothelial barrier properties. Am J Physiol Heart Circ Physiol. 2004;286:H394–H401
  108. Kouklis P, Konstantoulaki M, Vogel S, Broman M, Malik AB. Cdc42 regulates the restoration of endothelial barrier function. Circ Res. 2004;94:159–166
  109. Jacobson JR, Dudek SM, Birukov KG, et al. Cytoskeletal activation and altered gene expression in endothelial barrier regulation by simvastatin. Am J Respir Cell Mol Biol. 2004;30:662–670
  110. Hordijk PL, Anthony E, Mul FP, et al. Vascular–endothelial–cadherin modulates endothelial monolayer permeability. J Cell Sci. 1999;112(Pt. 12):1915–1923
  111. Yano Y, Saito Y, Narumiya S, Sumpio BE. Involvement of rho p21 in cyclic strain-induced tyrosine phosphorylation of focal adhesion kinase (pp125FAK), morphological changes and migration of endothelial cells. Biochem Biophys Res Commun. 1996;224:508–515
  112. van Nieuw Amerongen GPKP, Versteilen A, van Hinsbergh VW. Involvement of RhoA/Rho kinase signaling in VEGF-induced endothelial cell migration and angiogenesis in vitro. Arterioscler Thromb Vasc Biol. 2003;23:211–217
  113. Lee MJ, Thangada S, Claffey KP, et al. Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell. 1999;99:301–312
  114. Shiu YT, Li S, Marganski WA, et al. Rho mediates the shear-enhancement of endothelial cell migration and traction force generation. Biophys J. 2004;86:2558–2565
  115. Fujiwara H, Gu J, Sekiguchi K. Rac regulates integrin-mediated endothelial cell adhesion and migration on laminin-8. Exp Cell Res. 2004;292:67–77
  116. Soga N, Connolly JO, Chellaiah M, Kawamura J, Hruska KA. Rac regulates vascular endothelial growth factor stimulated motility. Cell Commun Adhes. 2001;8:1–13
  117. Gratzinger D, Canosa S, Engelhardt B, Madri JA. Platelet endothelial cell adhesion molecule-1 modulates endothelial cell motility through the small G-protein Rho. FASEB J. 2003;17:1458–1469
  118. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem. 1998;273:24266–24271
  119. Ming XF, Viswambharan H, Barandier C, et al. Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol Cell Biol. 2002;22:8467–8477
  120. Laufs U, Endres M, Stagliano N, et al. Neuroprotection mediated by changes in the endothelial actin cytoskeleton. J Clin Invest. 2000;106:15–24
  121. Hernández-Perera O, Perez Sala D, Soria E, Lamas S. Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells. Circ Res. 2000;87:616–622
  122. Schmeck B, Brunsch M, Seybold J, et al. Rho protein inhibition blocks cyclooxygenase-2 expression by proinflammatory mediators in endothelial cells. Inflammation. 2003;27:89–95
  123. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest. 1998;101:2711–2719
  124. Hippenstiel S, Schmeck B, Seybold J, et al. Reduction of tumor necrosis factor-alpha (TNF-alpha) related nuclear factor-kappaB (NF-kappaB) translocation but not inhibitor kappa-B (Ikappa-B)-degradation by Rho protein inhibition in human endothelial cells. Biochem Pharmacol. 2002;64:971–977
  125. Saito H, Minamiya Y, Kitamura M, et al. Endothelial myosin light chain kinase regulates neutrophil migration across human umbilical vein endothelial cell monolayer. J Immunol. 1998;161:1533–1540
  126. Garcia JG, Verin AD, Herenyiova M, English D. Adherent neutrophils activate endothelial myosin light chain kinase: role in transendothelial migration. J Appl Physiol. 1998;84:1817–1821
  127. Etienne-Manneville S, Manneville JB, Adamson P, et al. ICAM-1-coupled cytoskeletal rearrangements and transendothelial lymphocyte migration involve intracellular calcium signaling in brain endothelial cell lines. J Immunol. 2000;165:3375–3383
  128. van Wetering S, van den Berk N, van Buul JD, et al. VCAM-1-mediated Rac signaling controls endothelial cell–cell contacts and leukocyte transmigration. Am J Physiol Cell Physiol. 2003;285:343–352
  129. Alblas J, Ulfman L, Hordijk P, Koenderman L. Activation of Rhoa and ROCK are essential for detachment of migrating leukocytes. Mol Biol Cell. 2001;12:2137–2145
  130. Wojciak-Stothard B, Williams L, Ridley AJ. Monocyte adhesion and spreading on human endothelial cells is dependent on Rho-regulated receptor clustering. J Cell Biol. 1999;145:1293–1307
  131. Worthylake RA, Burridge K. Leukocyte transendothelial migration: orchestrating the underlying molecular machinery. Curr Opin Cell Biol. 2001;13:569–577
  132. Allen WE, Zicha D, Ridley AJ, Jones GE. A role for Cdc42 in macrophage chemotaxis. J Cell Biol. 1998;141:1147–1157
  133. Weber KS, Klickstein LB, Weber PC, Weber C. Chemokine-induced monocyte transmigration requires cdc42-mediated cytoskeletal changes. Eur J Immunol. 1998;28:2245–2251
  134. van Buul JD, Hordijk PL. Signaling in leukocyte transendothelial migration. Arterioscler Thromb Vasc Biol. 2004;24:824–833
  135. Worthylake RA, Lemoine S, Watson JM, Burridge K. RhoA is required for monocyte tail retraction during transendothelial migration. J Cell Biol. 2001;154:147–160
  136. Weber C, Erl W, Weber KS, Weber PC. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol. 1997;30:1212–1217
  137. Kimura M, Kurose I, Russell J, Granger DN. Effects of fluvastatin on leukocyte–endothelial cell adhesion in hypercholesterolemic rats. Arterioscler Thromb Vasc Biol. 1997;17:1521–1526
  138. Rasmussen LM, Hansen PR, Nabipour MT, et al. Diverse effects of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase on the expression of VCAM-1 and E-selectin in endothelial cells. Biochem J. 2001;360:363–370
  139. Yoshida M, Sawada T, Ishii H, et al. Hmg-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro: involvement of Rho GTPase-dependent mechanism. Arterioscler Thromb Vasc Biol. 2001;21:1165–1171
  140. Wei H, Fang L, Song J, Chatterjee S. Statin-inhibited endothelial permeability could be associated with its effect on PECAM-1 in endothelial cells. FEBS Lett. 2005;579:1272–1278
  141. Libby P, Schonbeck U. Drilling for oxygen: angiogenesis involves proteolysis of the extracellular matrix. Circ Res. 2001;89:195–197
  142. Ikeda U, Shimpo M, Ohki R, et al. Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells. Hypertension. 2000;36:325–329
  143. Wong B, Lumma WC, Smith AM, et al. Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation. J Leukoc Biol. 2001;69:959–962
  144. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002;90:251–262
  145. Miyata K, Shimokawa H, Kandabashi T, et al. Rho-kinase is involved in macrophage-mediated formation of coronary vascular lesions in pigs in vivo. Arterioscler Thromb Vasc Biol. 2000;20:2351–2358
  146. Argmann CA, Edwards JY, Sawyez CG, et al. Regulation of macrophage cholesterol efflux through HMG-CoA reductase inhibition: a role for RhoA in ABCA1-mediated cholesterol efflux. J Biol Chem. 2005;
  147. Senokuchi T, Matsumura T, Sakai M, et al. Statins suppress oxidized low density lipoprotein-induced macrophage proliferation by inactivation of the small G protein-p38 MAPK pathway. J Biol Chem. 2005;280:6627–6633
  148. Suzuki Y, Yamamoto M, Wada H, et al. Agonist-induced regulation of myosin phosphatase activity in human platelets through activation of Rho-kinase. Blood. 1999;93:3408–3417
  149. Liu Y, Suzuki YJ, Day RM, Fanburg BL. Rho kinase-induced nuclear translocation of ERK1/ERK2 in smooth muscle cell mitogenesis caused by serotonin. Circ Res. 2004;95:579–586
  150. Leng L, Kashiwagi H, Ren XD, Shattil SJ. RhoA and the function of platelet integrin alphaIIbbeta3. Blood. 1998;91:4206–4215
  151. Nishioka H, Horiuchi H, Tabuchi A, et al. Small GTPase Rho regulates thrombin-induced platelet aggregation. Biochem Biophys Res Commun. 2001;280:970–975
  152. Kunieda Y, Nakagawa K, Nishimura H, et al. HMG CoA reductase inhibitor suppresses the expression of tissue factor and plasminogen activator inhibitor-1 induced by angiotensin II in cultured rat aortic endothelial cells. Thromb Res. 2003;110:227–234
  153. Nishimura J, Sakihara C, Zhou Y, Kanaide H. Expression of rho A and rho kinase mRNAs in porcine vascular smooth muscle. Biochemical and biophysical research communications. 1996;227:750–754
  154. Kitazawa T, Gaylinn BD, Denney GH, Somlyo AP. G-protein-mediated Ca2+ sensitization of smooth muscle contraction through myosin light chain phosphorylation. J Biol Chem. 1991;266:1708–1715
  155. Gohla A, Schultz G, Offermanns S. Role for G(12)/G(13) in agonist-induced vascular smooth muscle cell contraction. Circ Res. 2000;87:221–227
  156. Sakurada S, Takuwa N, Sugimoto N, et al. Ca2+-dependent activation of Rho and Rho kinase in membrane depolarization-induced and receptor stimulation-induced vascular smooth muscle contraction. Circ Res. 2003;93:548–556
  157. Seasholtz TM, Zhang T, Morissette MR, et al. Increased expression and activity of RhoA are associated with increased DNA synthesis and reduced p27(Kip1) expression in the vasculature of hypertensive rats. Circ Res. 2001;89:488–495
  158. Borghi C. Interactions between hypercholesterolemia and hypertension: implications for therapy. Curr Opin Nephrol Hypertens. 2002;11:489–496
  159. Alvarez de Sotomayor M, Perez-Guerrero C, Herrera MD, Marhuenda E. Effect of simvastatin on vascular smooth muscle responsiveness: involvement of Ca(2+) homeostasis. Eur J Pharmacol. 2001;415:217–224
  160. Kuzuya M, Cheng XW, Sasaki T, Tamaya-Mori N, Iguchi A. Pitavastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, blocks vascular smooth muscle cell populated-collagen lattice contraction. J Cardiovasc Pharmacol. 2004;43:808–814
  161. Lyall FDM, Greer IA, Boswell F, Brown WC, McInnes GT. Mechanical stretch increases proto-oncogene expression and phosphoinositide turnover in vascular smooth muscle cells. J Hypertens. 1994;12:1139–1145
  162. Negoro N, Hoshiga M, Seto M, et al. The kinase inhibitor fasudil (HA-1077) reduces intimal hyperplasia through inhibiting migration and enhancing cell loss of vascular smooth muscle cells. Biochem Biophys Res Commun. 1999;262:211–215
  163. Ai S, Kuzuya M, Koike T, et al. Rho-Rho kinase is involved in smooth muscle cell migration through myosin light chain phosphorylation-dependent and independent pathways. Atherosclerosis. 2001;155:321–327
  164. Liu B, Itoh H, Louie O, Kubota K, Kent KC. The signaling protein Rho is necessary for vascular smooth muscle migration and survival but not for proliferation. Surgery. 2002;132:317–325
  165. Ryu Y, Takuwa N, Sugimoto N, et al. Sphingosine-1-phosphate, a platelet-derived lysophospholipid mediator, negatively regulates cellular Rac activity and cell migration in vascular smooth muscle cells. Circ Res. 2002;90:325–332
  166. Blindt R, Bosserhoff AK, Dammers J, et al. Downregulation of N-cadherin in the neointima stimulates migration of smooth muscle cells by RhoA deactivation. Cardiovasc Res. 2004;62:212–222
  167. Matsumoto Y, Uwatoku T, Oi K, et al. Long-term inhibition of Rho-kinase suppresses neointimal formation after stent implantation in porcine coronary arteries: involvement of multiple mechanisms. Arterioscler Thromb Vasc Biol. 2004;24:181–186
  168. Raiteri M, Arnaboldi L, McGeady P, et al. Pharmacological control of the mevalonate pathway: effect on arterial smooth muscle cell proliferation. J Pharmacol Exp Ther. 1997;281:1144–1153
  169. Stark WW, Blaskovich MA, Johnson BA, et al. Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells. Am J Physiol. 1998;275:L55–L63
  170. Shibata R, Kai H, Seki Y, et al. Role of Rho-associated kinase in neointima formation after vascular injury. Circulation. 2001;103:284–289
  171. Sawada N, Itoh H, Ueyama K, et al. Inhibition of rho-associated kinase results in suppression of neointimal formation of balloon-injured arteries. Circulation. 2000;101:2030–2033
  172. Sase K, Yui Y, Hattori R, et al. HA-1077 suppress both proliferation of vascular smooth muscle cells and c-fos mRNA induction. Jpn Circ J. 1992;56:1229–1233
  173. Pearce JD, Li J, Edwards MS, English WP, Geary RL. Differential effects of Rho-kinase inhibition on artery wall mass and remodeling. J Vasc Surg. 2004;39:223–228
  174. Shibata R, Kai H, Seki Y, et al. Rho-kinase inhibition reduces neointima formation after vascular injury by enhancing Bax expression and apoptosis. J Cardiovasc Pharmacol. 2003;42(Suppl. 1):S43–S47
  175. Li X, Liu L, Tupper JC, et al. Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells. J Biol Chem. 2002;277:15309–15316
  176. Petrache I, Crow MT, Neuss M, Garcia JG. Central involvement of Rho family GTPases in TNF-alpha-mediated bovine pulmonary endothelial cell apoptosis. Biochem Biophys Res Commun. 2003;306:244–249
  177. Guijarro C, Blanco-Colio LM, Ortego M, et al. 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res. 1998;83:490–500
  178. Guijarro C, Blanco-Colio LM, Massy ZA, et al. Lipophilic statins induce apoptosis of human vascular smooth muscle cells. Kidney Int Suppl. 1999;71:88–91
  179. Blanco Colio LM, Villa A, Ortego M, et al. 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis. 2002;161:17–26
  180. Littlewood TD, Bennett MR. Apoptotic cell death in atherosclerosis. Curr Opin Lipidol. 2003;14:469–475
  181. Worth NF, Rolfe BE, Song J, Campbell GR. Vascular smooth muscle cell phenotypic modulation in culture is associated with reorganisation of contractile and cytoskeletal proteins. Cell Motil Cytoskeleton. 2001;49:130–145
  182. Beqaj S, Jakkaraju S, Mattingly RR, Pan D, Schuger L. High RhoA activity maintains the undifferentiated mesenchymal cell phenotype, whereas RhoA down-regulation by laminin-2 induces smooth muscle myogenesis. J Cell Biol. 2002;156:893–903
  183. Bi D, Nishimura J, Niiro N, Hirano K, Kanaide H. Contractile properties of the cultured vascular smooth muscle cells the crucial role played by rhoa in the regulation of contractility. Circ Res. 2005;
  184. Yamakawa T, Tanaka S, Numaguchi K, et al. Involvement of Rho-kinase in angiotensin II-induced hypertrophy of rat vascular smooth muscle cells. Hypertension. 2000;35:313–318
  185. Zeidan ANI, Albinsson S, Malmqvist U, Sward K, Hellstrand P. Related articles links. Stretch-induced contractile differentiation of vascular smooth muscle: sensitivity to actin polymerization inhibitors. Am J Physiol Cell Physiol. 2003;284:C1387–C1396
  186. Albinsson S, Nordstrom I, Hellstrand P. Stretch of the vascular wall induces smooth muscle differentiation by promoting actin polymerization. J Biol Chem. 2004;279:34849–34855
  187. Mack CP, Thompson MM, Lawrenz Smith S, Owens GK. Smooth muscle a-actin CArG elements coordinate formation of a smooth muscle cell-selective, serum response factor-containing activation complex. Circ Res. 2000;86:221–232
  188. Gineitis D, Treisman R. Differential usage of signal transduction pathways defines two types of serum response factor target gene. J Biol Chem. 2001;276:24531–24539
  189. Sotiropoulos A, Gineitis D, Copeland J, Treisman R. Signal-regulated activation of serum response factor is mediated by changes in actin dynamics. Cell. 1999;98:159–169
  190. Camoretti Mercado B, Liu HW, Halayko AJ, et al. Physiological control of smooth muscle-specific gene expression through regulated nuclear translocation of serum response factor. J Biol Chem. 2000;275:30387–30393
  191. Liu HW, Halayko AJ, Fernandes DJ, et al. The RhoA/Rho kinase pathway regulates nuclear localization of serum response factor. Am J Respir Cell Mol Biol. 2003;29:39–47
  192. Chen J, Kitchen CM, Streb JW, Miano JM. Myocardin: a component of a molecular switch for smooth muscle differentiation. J Mol Cell Cardiol. 2002;34:1345–1356
  193. Lockman K, Hinson JS, Medlin MD, et al. Sphingosine 1-phosphate stimulates smooth muscle cell differentiation and proliferation by activating separate serum response factor co-factors. J Biol Chem. 2004;279:42422–42430
  194. Wassmann S, Laufs U, Baumer AT, et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol. 2001;59:646–654
  195. Napoli C, de Nigris F, Palinski W. Multiple role of reactive oxygen species in the arterial wall. J Cell Biochem. 2001;82:674–682
  196. Collins T. Endothelial nuclear factor-kappa B and the initiation of the atherosclerotic lesion. Lab Invest. 1993;68:499–508
  197. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000;87:840–844
  198. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res. 2000;86:494–501
  199. Lassegue B, Clempus RE. Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol. 2003;285:R277–R297
  200. Mollnau H, Wendt M, Szocs K, et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res. 2002;90:E58–E65
  201. De Keulenaer GW, Chappell DC, Ishizaka N, et al. Oscillatory and steady laminar shear stress differentially affect human endothelial redox state: role of a superoxide-producing NADH oxidase. Circ Res. 1998;82:1094–1101
  202. Bokoch GM, Diebold BA. Current molecular models for NADPH oxidase regulation by Rac GTPase. Blood. 2002;100:2692–2696
  203. Seshiah PN, Weber DS, Rocic P, et al. Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ Res. 2002;91:406–413
  204. Deshpande SS, Qi B, Park YC, Irani K. Constitutive activation of rac1 results in mitochondrial oxidative stress and induces premature endothelial cell senescence. Arterioscler Thromb Vasc Biol. 2003;23:e1–e6
  205. Wagner AH, Kohler T, Ruckschloss U, Just I, Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol. 2000;20:61–69
  206. Takemoto M, Node K, Nakagami H, et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest. 2001;108:1429–1437
  207. Wassmann S, Laufs U, Muller K, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol. 2002;22:300–305
  208. Diebold BA, Fowler B, Lu J, Dinauer MC, Bokoch GM. Antagonistic cross-talk between Rac and Cdc42 GTPases regulates generation of reactive oxygen species. J Biol Chem. 2004;279:28136–28142
  209. Higashi M, Shimokawa H, Hattori T, et al. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ Res. 2003;93:767–775
  210. Jin L, Ying Z, Webb RC. Activation of Rho/Rho kinase signaling pathway by reactive oxygen species in rat aorta. Am J Physiol Heart Circ Physiol. 2004;287:H1495–H1500
  211. Raines EW. The extracellular matrix can regulate vascular cell migration, proliferation, and survival: relationships to vascular disease. Int J Exp Pathol. 2000;81:173–182
  212. Fulop T, Jacob MP, Khalil A, Wallach J, Robert L. Biological effects of elastin peptides. Pathol Biol (Paris). 1998;46:497–506
  213. Katsuda S, Okada Y, Minamoto T, et al. Collagens in human atherosclerosis Immunohistochemical analysis using collagen type-specific antibodies. Arterioscler Thromb. 1992;12:494–502
  214. Merrilees MJ, Beaumont B, Scott LJ. Comparison of deposits of versican, biglycan and decorin in saphenous vein and internal thoracic, radial and coronary arteries: correlation to patency. Coron Artery Dis. 2001;12:7–16
  215. Riessen R, Isner JM, Blessing E, et al. Regional differences in the distribution of the proteoglycans biglycan and decorin in the extracellular matrix of atherosclerotic and restenotic human coronary arteries. Am J Pathol. 1994;144:962–974
  216. Lin H, Wilson JE, Roberts CR, et al. Biglycan, decorin, and versican protein expression patterns in coronary arteriopathy of human cardiac allograft: distinctness as compared to native atherosclerosis. J Heart Lung Transplant. 1996;15:1233–1247
  217. Siegel-Axel DI, Runge H, Seipel L, Riessen R. Effects of cerivastatin on human arterial smooth muscle cell growth and extracellular matrix expression at varying glucose and low-density lipoprotein levels. J Cardiovasc Pharmacol. 2003;41:422–433
  218. Fukumoto Y, Libby P, Rabkin E, et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation. 2001;103:993–999
  219. Hatano H, Maruo A, Bolander ME, Sarkar G. Statin stimulates bone morphogenetic protein-2, aggrecan, and type 2 collagen gene expression and proteoglycan synthesis in rat chondrocytes. J Orthop Sci. 2003;8:842–848
  220. Ikeuchi H, Kuroiwa T, Yamashita S, et al. Fluvastatin reduces renal fibroblast proliferation and production of type III collagen: therapeutic implications for tubulointerstitial fibrosis. Nephron Exp Nephrol. 2004;97:e115–e122
  221. Nishimura M, Tanaka T, Yasuda T, et al. Collagen secretion and growth of mesangial cells require geranylgeranylpyrophosphate. Kidney Int. 1999;55:520–528
  222. Deroanne CF, Hamelryckx D, Ho TT, et al. Cdc42 downregulates MMP-1 expression by inhibiting the ERK1/2 pathway. J Cell Sci. 2005;118:1173–1183
  223. Ang AH, Tachas G, Campbell JH, Bateman JF, Campbell GR. Collagen synthesis by cultured rabbit aortic smooth-muscle cells. Alteration with phenotype. Biochem J. 1990;265:461–469
  224. Sahai E, Alberts AS, Treisman R. RhoA effector mutants reveal distinct effector pathways for cytoskeletal reorganization SRF activation and transformation. EMBO J. 1998;17:1350–1361
  225. Masszi A, Di Ciano C, Sirokmany G, et al. Central role for Rho in TGF-beta1-induced alpha-smooth muscle actin expression during epithelial-mesenchymal transition. Am J Physiol Renal Physiol. 2003;284:E911–E924
  226. Sahai E, Marshall CJ. ROCK and Dia have opposing effects on adherens junctions downstream of Rho. Nat Cell Biol. 2002;4:408–415
  227. Sahai E, Olson MF, Marshall CJ. Cross-talk between Ras and Rho signalling pathways in transformation favours proliferation and increased motility. EMBO J. 2001;20:755–766
  228. Ohmori T, Yatomi Y, Osada M, et al. Sphingosine 1-phosphate induces contraction of coronary artery smooth muscle cells via S1P2. Cardiovasc Res. 2003;58:170–177
  229. Zhou H, Murthy KS. Distinctive G protein-dependent signaling in smooth muscle by sphingosine 1-phosphate receptors S1P1 and S1P2. Am J Physiol Cell Physiol. 2004;286:C1130–C1138
  230. Sugimoto N, Takuwa N, Okamoto H, Sakurada S, Takuwa Y. Inhibitory and stimulatory regulation of Rac and cell motility by the G12/13-Rho and Gi pathways integrated downstream of a single G protein-coupled sphingosine-1-phosphate receptor isoform. Mol Cell Biol. 2003;23:1534–1545
  231. Kluk MJ, Hla T. Role of the sphingosine 1-phosphate receptor EDG-1 in vascular smooth muscle cell proliferation and migration. Circ Res. 2001;89:496–502
  232. An S, Zheng Y, Bleu T. Sphingosine 1-phosphate-induced cell proliferation, survival, and related signaling events mediated by G protein-coupled receptors Edg3 and Edg5. J Biol Chem. 2000;275:288–296
  233. Paik JH, Chae S, Lee MJ, Thangada S, Hla T. Sphingosine-1-phosphate-induced endothelial cell migration requires the expression of EDG-1 and EDG-3 receptors and Rho-dependent activation of avb3- and b1-containing integrins. J Biol Chem. 2001;276:11830–11837
  234. Chang PS, Li L, McAnally J, Olson EN. Muscle specificity encoded by specific serum response factor-binding sites. J Biol Chem. 2001;276:17206–17212
  235. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev. 2004;84:767–801
  236. Wang DZ, Li S, Hockemeyer D, et al. Potentiation of serum response factor activity by a family of myocardin-related transcription factors. Proc Natl Acad Sci USA. 2002;99:14855–14860

PII: S0021-9150(05)00308-4

doi: 10.1016/j.atherosclerosis.2005.04.023

Atherosclerosis
Volume 183, Issue 1 , Pages 1-16 , November 2005

Article Tools

* Image Usage & Resolution